CRESCENT BIOPHARMA, INC. (CBIO) Financial Statements
CRESCENT BIOPHARMA, INC. (CBIO) reported trailing twelve-month revenue of $11.9M (up 177.4% year on year) and net income of -$96.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$73.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CBIOCRESCENT BIOPHARMA, INC.Follow CBIO — free
—
Price chart with a free account
- Market cap
- 476.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.0 | 20.1 | 0.0 | 10.2 | 1.2 | 0.1 | 0.0 | 10.8 | 11.9 | |
| Research & development | 19.6 | 25.1 | 23.3 | 44.9 | 47.5 | 28.4 | 20.1 | 138.1 | 152.7 | |
| Operating income | -11.1 | -12.8 | -31.9 | -51.5 | -63.4 | -47.4 | -39.3 | -152.6 | -168.5 | |
| Pre-tax income | — | — | — | -51.0 | — | — | — | -151.9 | -163.1 | |
| Income tax | — | — | — | — | — | — | — | 2.0 | 2.0 | |
| Net income | -11.1 | -12.8 | -31.8 | -51.0 | -63.4 | -46.7 | -36.9 | -153.9 | -96.0 | |
| Diluted EPS ($) | -0.60 | -0.67 | -1.50 | -1.12 | -1.23 | -0.89 | -0.58 | — | — | |
| Diluted shares (mn) | 18.5 | — | — | 45.7 | 51.5 | 52.5 | 63.3 | — | — |
USD millions · SEC XBRL
CRESCENT BIOPHARMA, INC. — questions
- What is CRESCENT BIOPHARMA, INC.'s revenue?
- $11.9M over the twelve months to 2026-06-30, up 177.4% year on year, from its 10-Q and 10-K filings.
- What is CRESCENT BIOPHARMA, INC.'s net income?
- -$96.0M over the twelve months to 2026-06-30.
- What is CRESCENT BIOPHARMA, INC.'s free cash flow?
- -$73.6M over the twelve months to 2026-06-30.
Every figure on this page comes from CRESCENT BIOPHARMA, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.